Abstract
The clinical use of amantadine for influenza A viruses infection is increasing. A novel quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assay was developed to determine the IC50 (dose of 50% inhibitory) of amantadine. The traditional amantadine susceptibility testing by plaque inhibition assay took 3 days to observe plaque formation. In contrast, the proposed assay took 3 hours to detect vital RNA. The RT-PCR products can be directly sequenced for screening and identifying the resistant strains.
Original language | English |
---|---|
Pages (from-to) | 873-878 |
Number of pages | 6 |
Journal | Biotechnology Techniques |
Volume | 11 |
Issue number | 12 |
DOIs | |
State | Published - 1997 |
Externally published | Yes |